News

Jardiance filed in Japan for chronic kidney disease

Read time: 1 mins

Published:2nd Feb 2023

Nippon Boehringer Ingelheim and Eli Lilly Japan said on January 31 that their SGLT2 inhibitor Jardiance (empagliflozin) was filed with Japanese regulatory authorities for an additional indication of chronic kidney disease (CKD)

The submission follows data from the global PIII EMPA-KIDNEY trial, which enrolled 6,609 participants diagnosed with CKD including Japanese. In the study, Jardiance on top of standard of care significantly cut the risk of CKD progression or cardiovascular death by 28% versus placebo.

Condition: Chronic Kidney Disease/CKD

Type: drug

patient receiving dialysis, hospital image

Learning Zone Homepage

Chronic Kidney Disease Learning Zone

Chronic Kidney Disease (CKD) is a disease that can often lead to a need for haemodialysis and kidney transplantation. New CKD treatments are emerging which focus on delaying CKD disease progression and the need for transplantation.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

Eplontersen demonstrated sustained benefit in Phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) through 66 weeks.- AstraZeneca + Ionis

Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed eplontersen met its co-primary endpoints through 66 weeks. The results were consistent with the positive 35-week findings announced in June 2022.

2 mins

Drug news

Kisqali phase III NATALEE trial meets primary endpoint at interim analysis demonstrating clinically meaningful benefit in broad population of patients with early breast cancer.- Novartis

Novartis announced positive topline results from an interim analysis of NATALEE, a Phase III trial evaluating Kisqali (ribociclib) plus endocrine therapy (ET) in a broad population of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (EBC) at risk of recurrence.

2 min

Drug news

Completion of BLA application submission for lifileucel in advanced melanoma.- Iovance Biotherapeutics Inc.,

Iovance Biotherapeutics, Inc. announced it has completed its rolling Biologics License Application (BLA) submission to the FDA for lifileucel. Lifileucel is a tumor infiltrating lymphocyte (TIL) therapy intended as a treatment for patients with advanced (unresectable or metastatic) melanoma who progressed on or after prior anti-PD-1/L1 therapy and targeted therapy, where applicable. There are no FDA approved therapies in this treatment setting.

1 min

See all news